The world at large received the gifts of hope and relief this year when not only one, but three, Covid-19 vaccinations became available to the masses. Prior to this “light at the end of the tunnel,” the entire world was effected by the uncertainty and negative impacts from the Covid-19 pandemic. During that difficult time, DaVita Clinical Research (DCR) completed two Covid-19-oriented studies in order to better understand the virus and help the future of not only the renal industry, but the health industry as a whole.
DCR is very excited to announce that our publication about this research, “Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis” was accepted and published by the Journal of the American Society of Nephrology (JASN) in July 2021! Click here to view the publication.
We are excited to continue to contemplate new and innovative ways to conduct studies with this population to better understand COVID-19 as well as its response to the newly available vaccinations. We also hope to better the renal industry’s ability to improve and maintain patient health and safety, and our broader understanding COVID-19. To learn more about how DaVita Clinical Research is spearheading essential renal research, click here.